Patent · US Active

Method of enhancing KSHV LANA1 immunogenicity

US9402895B2 · kind B2 · utility

2Cited by

0References

6Claims

0Family size

Assignee

University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

Yuan Chang · New York, US
Patrick S. Moore · New York, US

Key dates

Filing date	Dec 22, 2011
Grant date	Aug 2, 2016
Priority date	—
Expiry date	May 18, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16471
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.